Clinical Trial Update: STOP-T1D Low-Dose (ATG) [Phase 2]

View source ↗

Summary

The STOP-T1D Low-Dose ATG Phase 2 trial for type 1 diabetes mellitus has been terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Type 1 Diabetes Mellitus

Drugs mentioned

• Antithymocyte Globulin (ATG) (antithymocyte globulin)

Snippet

Sponsor: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) | Conditions: Diabetes Mellitus, Type 1 | Phase 2 | Status: TERMINATED